Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 13Thyroid Carcinoma, Anaplastic 4Squamous Cell Carcinoma of Head and Neck 4Salivary Gland Neoplasms 4Carcinoma, Medullary 4Tongue Neoplasms 3Thyroid Diseases 3Thyroid Cancer, Papillary 3Head and Neck Neoplasms 2Adenocarcinoma, Follicular 2Wilms Tumor 1Thyroid cancer, medullary 1Thyroid cancer, Hurthle cell 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Nasopharyngeal Neoplasms 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Mesothelioma 1Lung Neoplasms 1Locally Advanced Thyroid Gland Carcinoma 1Familial medullary thyroid carcinoma 1Differentiated Thyroid Cancer 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1

Interventions

vandetanib 2Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Familial medullary thyroid carcinoma × Sorafenib × Head & Neck × Clear all
NCT00390325 2024-02-06

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Completed
21 enrolled 15 charts
EndocrineHead & Neck

Familial medullary thyroid carcinoma, Carcinoma, Medullary, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡